Title A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Principal Investigator Saby George, MD
Study Number 225212
Summary To compare the clinical benefit, as measured by the duration of OS, provided by BMS-936558 vs everolimus in subjects with advanced or metastatic renal cell carcinoma who have received prior anti-angiogenic therapy.
Eligibility Please see ClinicalTrials.gov link.